{"schema_version":"secwatch.filing_event.v1","accession":"0001625297-25-000046","form_type":"8-K","ticker":"INDV","cik":"0001625297","company_name":"Indivior Pharmaceuticals, Inc.","filed_at":"2025-06-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.106033+00:00","generated_at":"2026-05-18T13:10:57.254760+00:00","sec_items":["7.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Indivior added to Russell 2000 and 3000 indexes effective June 30, 2025","bullets":["Inclusion follows 2025 Russell indexes annual reconstitution; membership lasts one year.","CEO notes 85% of 2024 net revenue was U.S.-generated, mainly from SUBLOCADE.","About $10.6 trillion in assets benchmarked to U.S. Russell indexes (FTSE Russell data).","Stock also automatically added to corresponding growth and value indexes."],"urls":{"canonical":"https://secwatch.observer/filing/0001625297-25-000046","json":"https://secwatch.observer/filing/0001625297-25-000046.json","markdown":"https://secwatch.observer/filing/0001625297-25-000046.md","text":"https://secwatch.observer/filing/0001625297-25-000046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625297/000162529725000046/0001625297-25-000046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625297/000162529725000046/indv-20250630.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T13:10:57.254760+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}